Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.

International journal of oncology

Volumn 16, Issue 4, 2000, Pages 769-776

  Riccardi, A ^a   Tinelli, C ^a   Brugnatelli, S ^a   Pugliese, P ^a   Giardina, V ^a   Giordano, M ^a   Danova, M ^a   Richetti, A ^a   Fava, S ^a   Rinaldi, E ^a   Fregoni, V ^a   Trotti, G ^a   Poli, A ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE;

MLCS; MLOWN;

EID: 0034164637     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.16.4.769     Document Type: Article

References (0)